Vaccine List

Adacel

(diphtheria, tetanus acellular, and pertussis adult vaccine - also called Tdap) is used to help prevent tetanus, diphtheria, and pertussis in people who are at least 10 years old. Most people in this age group require only one Tdap shot for protection against these diseases.

Afluria

Afluria is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine.

Boostrix

BOOSTRIX is a vaccine indicated for active booster immunization against tetanus, diphtheria, and pertussis. BOOSTRIX is approved for use as a single dose in individuals 10 years of age and older.

Engerix-B

ENGERIX-B is a vaccine indicated for immunization against infection caused by all known subtypes of hepatitis B virus.

Fluad

FLUAD is a vaccine that helps protect against the flu. FLUAD is for people aged 65 years and older. Vaccination with FLUAD may not protect all people who receive the vaccine.

Fluarix Quadrivalent

FLUARIX QUADRIVALENT is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUARIX QUADRIVALENT is approved for use in persons aged 3 years and older.

Flublok

Flublok and Flublok Quadrivalent vaccines are given to people 18 years of age and older to help prevent influenza disease caused by influenza A virus subtypes and influenza type B virus contained in the vaccine. 

Flucelvax

FLUCELVAX QUADRIVALENT is a vaccine that helps protect against influenza (flu). FLUCELVAX is for people aged 4 and older. Vaccination with FLUCELVAX QUADRIVALENT may not protect all people who receive the vaccine.

Flulaval Quadrivalent

FLULAVAL QUADRIVALENT is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLULAVAL QUADRIVALENT is approved for use in persons aged 6 months and older.

Flumist Quadrivalent

The Advisory Committee on Immunization Practices (ACIP) recommended that FluMist Quadrivalent not be used for the 2016-2017 season.

FluMist Quadrivalent is a vaccine that is sprayed into the nose to help protect against influenza. It can be used in children, adolescents, and adults ages 2 through 49. FluMist Quadrivalent is similar to MedImmune’s trivalent influenza vaccine, except FluMist Quadrivalent provides protection against an additional influenza strain. FluMist Quadrivalent may not prevent influenza in everyone who gets vaccinated.

Fluvirin

FLUVIRIN® (Influenza Virus Vaccine) is an inactivated subunit influenza virus vaccine indicated for active immunization of persons aged 4 years and older against influenza disease caused by influenza virus subtypes A and B included in the vaccine.

Fluzone

Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, and Fluzone High-Dose vaccines are given to help prevent influenza disease caused by influenza A and B strains contained in each vaccine. Fluzone Quadrivalent vaccine is given to people 6 months of age and older. Fluzone Intradermal Quadrivalent vaccine is given to people 18 through 64 years of age. Fluzone High-Dose vaccine is given to people 65 years of age and older.

Fluzone High-Dose

Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, and Fluzone High-Dose vaccines are given to help prevent influenza disease caused by influenza A and B strains contained in each vaccine. Fluzone High-Dose vaccine is given to people 65 years of age and older.

Fluzone Intradermal

Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, and Fluzone High-Dose vaccines are given to help prevent influenza disease caused by influenza A and B strains contained in each vaccine. Fluzone Intradermal Quadrivalent vaccine is given to people 18 through 64 years of age. How Is an Intradermal Flu Shot Different? Typical flu shots are intramuscular, which means they go through the skin, a layer of fat, and then the muscle. Intradermal vaccines are injected into the skin through a small, ultra-thin needle.3,4 And since the skin has more specialized immune cells than the muscle, the intradermal vaccine can provide a similar level of protection as the traditional flu shot.

Fluzone Quadrivalent

Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, and Fluzone High-Dose vaccines are given to help prevent influenza disease caused by influenza A and B strains contained in each vaccine. Fluzone Quadrivalent vaccine is given to people 6 months of age and older.

Gardasil

GARDASIL is a vaccine indicated in girls and women 9 through 26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16 and 18, Genital warts (condyloma acuminata) caused by HPV types 6 and 11  And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervical adenocarcinoma in situ (AIS);  Cervical intraepithelial neoplasia (CIN) grade 1; Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3; Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3

Gardasil 9

GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) helps protect girls and women ages 9 to 26 against cervical, vaginal, vulvar, and anal cancers and genital warts caused by 9 types of HPV. GARDASIL 9 helps protect boys and men ages 9 to 26 against anal cancer and genital warts caused by those same HPV types.
GARDASIL 9 may not fully protect everyone, nor will it protect against diseases caused by other HPV types or against diseases not caused by HPV.
GARDASIL 9 does not prevent all types of cervical cancer, so it’s important for women to continue routine cervical cancer screenings. GARDASIL 9 does not treat cancer or genital warts.
GARDASIL 9 is a shot that is usually given in the arm muscle. GARDASIL 9 may be given as 2 or 3 shots.

Harvoni

HARVONI is a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C (Hep C) genotype (GT) 1, 4, 5 or 6 infection with or without cirrhosis (compensated). In those with GT 1 and advanced cirrhosis (decompensated) or with GT 1 or 4 with or without cirrhosis (compensated) who have had a liver transplant, HARVONI is used with ribavirin.

Havrix

HAVRIX is a vaccine indicated for active immunization against disease
caused by hepatitis A virus (HAV). HAVRIX is approved for use in persons
12 months of age and older. Primary immunization should be administered at
least 2 weeks prior to expected exposure to HAV.

Hepagam B

HepaGam B® [Hepatitis B Immune Globulin Intravenous (Human)] is an intravenous immune globulin indicated for the following: Prevention of Hepatitis B recurrence following liver transplant in HBsAg-positive liver transplant patients.  Post-exposure prophylaxis including: Acute exposure to HBsAg-positive blood, plasma, or serum (parenteral exposure, direct mucus membrane contact, oral ingestion, etc.), Perinatal exposure of infants born to HBsAg-positive mothers, Sexual exposure to HBsAg-positive persons, and Household exposure to persons with acute HBV infection.

Imovax

Imovax Rabies is a vaccine indicated for pre-exposure and post-exposure prophylaxis against rabies.
Imovax Rabies vaccine is approved for use in all age groups.

Menactra

Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis serogroup B disease.

Menhibrix

MENHIBRIX is a vaccine indicated for active immunization to prevent
invasive disease caused by Neisseria meningitidis serogroups C and Y and
Haemophilus influenzae type b. MENHIBRIX is approved for use in children
6 weeks of age through 18 months of age.

Menveo

MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections.

MMR II

M-M-R ® II is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months of age or older.

Pedvaxhib

PedvaxHIB is indicated for routine vaccination against invasive disease caused by Haemophilus influenzae type b in infants and children 2 to 71 months of age. PedvaxHIB should not be used in infants <6 weeks of age.

PennVax-GP

PENNVAX®-GP is a developmental vaccine to prevent and treat HIV strains primarily present in Africa, Asia, Europe, and North America. It is intended to induce broad antibody and T-cell immune responses. This multi-subtype vaccine is based on optimized synthetic immunogens targeting two env antigens as well as gag and pol antigens—providing global coverage against HIV-1 subtypes. It is delivered using Inovio’s CELLECTRA® electroporation device. PENNVAX-GP is our lead preventive and therapeutic HIV DNA vaccine candidate. A phase I study is currently being conducted in collaboration with the HIV Vaccine Trials Network (HVTN).

Inovio’s PENNVAX-GP HIV vaccine is also being tested in combination with other novel DNA vaccine constructs encoding for new HIV envelope proteins in a five year preclinical program. Preclinical studies are being funded by the National Institute of Allergy and Infectious Diseases (NIAID).

Pneumovax 23

PNEUMOVAX ® 23 (Pneumococcal Vaccine Polyvalent) is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

Prevnar 13

Prevnar 13® is a vaccine indicated in children 6 weeks through 17 years (prior to the 18th birthday) for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and for children 6 weeks through 5 years of age (prior to the 6th birthday) for the prevention of otitis media caused by 7 of the 13 serotypes in the vaccine
In adults 18 years of age and older, Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by S. pneumoniae serotypes in the vaccine
Prevnar 13® does not protect against disease caused by S. pneumoniae serotypes that are not in the vaccine

Proquad

ProQuad is a vaccine indicated for active immunization for the prevention of measles, mumps, rubella, and varicella in children 12 months through 12 years of age.

Rabavert

RABAVERT is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups.

Recombivax HB

RECOMBIVAX HB is indicated for prevention of infection caused by all known subtypes of hepatitis B virus. RECOMBIVAX HB is approved for use in individuals of all ages. RECOMBIVAX HB Dialysis Formulation is approved for use in adult predialysis and dialysis patients 18 years of age and older.

Rotarix

ROTARIX is a vaccine indicated for the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) when administered as a 2-dose series. ROTARIX is approved for use in infants 6 weeks to 24 weeks of age.

Rotateq

RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.

Stamaril

Sanofi Pasteur confirms that YF-VAX® (Yellow Fever Vaccine) is unavailable to order in the U.S. until mid-2018 as the company transitions production to a new state-of-the-art facility, which is expected to occur in 2018.

Sanofi Pasteur has worked with the FDA to make another yellow fever vaccine available in the US through an Expanded Access Investigational New Drug Application (IND). Manufactured by Sanofi Pasteur in France, this vaccine, STAMARIL® (Yellow Fever Vaccine [Live]), is registered and distributed in over 70 countries. However, it is considered investigational in the US, as it is not a US-licensed product.

The Expanded Access Program has requirements similar to a clinical trial; thus Sanofi Pasteur can support only a limited number of sites. Working closely with the CDC, geographically distributed sites throughout the US were identified for inclusion in the program so patients can have continued access to yellow fever vaccine.

Trumenba

Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B
The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed

Truvada

TRUVADA for PrEP (pre-exposure prophylaxis) is a prescription medicine that is used together with safer sex practices to help reduce the risk of getting HIV-1 through sex. This use is only for HIV-negative adults who are at high risk of getting HIV-1. To help determine your risk of getting HIV-1, talk openly with your healthcare provider about your sexual health.

Twinrix

TWINRIX is a vaccine indicated for active immunization against disease
caused by hepatitis A virus and infection by all known subtypes of hepatitis B
virus. TWINRIX is approved for use in persons 18 years of age or older.

Typhim VI

TYPHIM Vi is a sterile solution, prepared from the purified polysaccharide capsule of
Salmonella typhi (Ty 2 strain). The purified polysaccharide capsule is diluted in
isotonic buffer solution which contains phenol as preservative. The vaccine is a clear,
colourless solution. Each single dose of 0.5 mL is formulated to contain 0.025
milligrams of purified capsular polysaccharide, preserved with phenol (less than 1.25
mg per dose). The isotonic buffer solution contains 4.15 mg of sodium chloride,
0.065 mg of sodium phosphate dibasic dihydrate and 0.023 mg of sodium phosphate
monobasic.

Vaqta

VAQTA is indicated for the prevention of disease caused by hepatitis A virus (HAV) in persons 12 months of age and older. The primary dose should be given at least 2 weeks prior to expected exposure to HAV.

Varivax

VARIVAX is a vaccine indicated for active immunization for the prevention of varicella in individuals 12 months of age or older.
Each dose is approximately 0.5 mL after reconstitution and is administered by subcutaneous injection.

Varizig

VARIZIG [Varicella Zoster Immune Globulin (Human)] is indicated in the United States for post-exposure prophylaxis of varicella (chickenpox) in high risk patient groups including immunocompromised children, newborns, and pregnant women. VARIZIG is intended to reduce the severity of chickenpox infections in these patients.

Vaxchora

Vaxchora is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1 in adults 18 through 64 years of age traveling to cholera-affected areas.

Vivotif

Vivotif is an oral vaccine for typhoid fever, a potentially severe and life-threatening infection caused by the bacterium Salmonella enterica serotype Typhi ( S Typhi).
Taken orally, the vaccine is delivered to the mucosal surface of the gastrointestinal tract—the largest immunologic organ in the body.

YF-VAX

YF-VAX is indicated for active immunization for the prevention of yellow fever in persons 9
months of age and older in the following categories: Persons Living in or Traveling to Endemic Areas,
Persons Travelling Internationally Through Countries with Yellow Fever, Laboratory Personnel

Zostavax

ZOSTAVAX is a single shot vaccine for adults 50 years of age or older that helps to boost the immune system against Shingles.
ZOSTAVAX cannot be used to treat Shingles or the nerve pain that may follow Shingles, once you have it.